Challenge for Adverse Outcome Pathway (AOP)-based Chemical Safety Assessment

被引:2
|
作者
Yamada, Takashi [1 ]
Ashikaga, Takao [1 ]
Kojima, Hajime [1 ]
Hirose, Akihiko [1 ]
机构
[1] Natl Inst Hlth Sci, Ctr Biol Safety & Res, Div Risk Assessment, Kawasaki Ku, 3-25-26 Tonomachi, Kawasaki, Kanagawa 2109501, Japan
关键词
adverse outcome pathway; chemical; in silico; integrated approaches to testing and assessment; Organisation for Economic Co-operation and Development;
D O I
10.1248/yakushi.19-00190-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The latest chemical management policies require toxicological evaluation of marketed but untested chemicals. Furthermore, in Europe, for animal welfare reasons sales of cosmetics and raw materials for which animal experiments were conducted were totally banned, in 2013. Responding to these regulatory trends, a strong demand exists to develop new in vitro test methods and to improve in silico prediction models for safety assessments. In recent years, the development of adverse outcome pathways (AOPs) has been actively promoted in the Organisation for Economic Co-operation and Development (OECD). Since it is difficult to replace a particular in vivo animal test with a single in vitro test method or in silico prediction model, integrated approaches to testing and assessment (IATA) have been studied based on AOP information. With regard to skin sensitization, several in vitro test methods that measure key events of AOP have been established, and integrated strategies using in vitro tests have been examined using AOP. Currently, numerous AOPs are under development for a wide range of complex toxicity endpoints in the OECD AOP program. The AOPs are expected to contribute to the development of many accurate in vitro test methods and to establish IATA as well as to evaluate safety in humans of many substances, including household chemicals, food-related chemicals, cosmetics, and pharmaceuticals.
引用
收藏
页码:481 / 484
页数:4
相关论文
共 50 条
  • [1] Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research
    Olavi Pelkonen
    Andrea Terron
    Antonio F. Hernandez
    Pablo Menendez
    Susanne Hougaard Bennekou
    Archives of Toxicology, 2017, 91 : 2763 - 2780
  • [2] Chemical exposure and infant leukaemia: development of an adverse outcome pathway (AOP) for aetiology and risk assessment research
    Pelkonen, Olavi
    Terron, Andrea
    Hernandez, Antonio F.
    Menendez, Pablo
    Bennekou, Susanne Hougaard
    ARCHIVES OF TOXICOLOGY, 2017, 91 (08) : 2763 - 2780
  • [3] Applying the skin sensitisation adverse outcome pathway (AOP) to quantitative risk assessment
    Maxwell, Gavin
    MacKay, Cameron
    Cubberley, Richard
    Davies, Michael
    Gellatly, Nichola
    Glavin, Stephen
    Gouin, Todd
    Jacquoilleot, Sandrine
    Moore, Craig
    Pendlington, Ruth
    Saib, Ouarda
    Sheffield, David
    Stark, Richard
    Summerfield, Vicki
    TOXICOLOGY IN VITRO, 2014, 28 (01) : 8 - 12
  • [4] The adverse outcome pathway (AOP) for chemical binding to tubulin in oocytes leading to aneuploid offspring
    Marchetti, Francesco
    Massarotti, Alberto
    Yauk, Carole L.
    Pacchierotti, Francesca
    Russo, Antonella
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2016, 57 (02) : 87 - 113
  • [6] A proposal for the adverse outcome pathway (AOP) for food sensitization
    Van Bilsen, J. H.
    Sienkiewicz-Szlapka, E.
    Lozano-Ojalvo, D.
    Willemsen, L. E.
    Antunes, C.
    Molina, E.
    Smit, J. J.
    Wroblewska, B.
    Wichers, H. J.
    Knol, E.
    Ladics, G. S.
    Pieters, R. H.
    Denery-Papini, S.
    Vissers, Y. M.
    Bavaro, S. L.
    Larre, C.
    Verhoeckx, K. C.
    Roggen, E. L.
    ALLERGY, 2017, 72 : 4 - 4
  • [7] Development Of An Adverse Outcome Pathway (AOP) Network For Carcinogenicity
    Cayley, A. N.
    Foster, R.
    Kane, S.
    Stalford, S. A.
    Williams, R., V
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2018, 59 : 64 - 64
  • [8] Application of the Adverse Outcome Pathway (AOP) Approach for Cardiotoxicity Adverse Endpoints
    Prior, Helen
    Sewell, Fiona
    Landesmann, Brigitte
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2017, 88 : 201 - 202
  • [9] Applying the adverse outcome pathway framework for safety assessment of medical implants: towards an AOP network for implant-induced fibrosis
    Alsema, E. C.
    Braakhuis, H. M.
    De Boer, J.
    Beijer, N. R. M.
    TOXICOLOGY LETTERS, 2022, 368 : S237 - S237
  • [10] Adverse Outcome Pathway (AOP) Development I: Strategies and Principles
    Villeneuve, Daniel L.
    Crump, Doug
    Garcia-Reyero, Natalia
    Hecker, Markus
    Hutchinson, Thomas H.
    LaLone, Carlie A.
    Landesmann, Brigitte
    Lettieri, Teresa
    Munn, Sharon
    Nepelska, Malgorzata
    Ottinger, Mary Ann
    Vergauwen, Lucia
    Whelan, Maurice
    TOXICOLOGICAL SCIENCES, 2014, 142 (02) : 312 - 320